Navigation Links
Vicor Technologies announces results of PD2i analysis of MUSIC trial data
Date:5/19/2010

Boca Raton, FL May 19, 2010 David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca (MUSIC) Trial using its PD2i algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i nonlinear algorithm and software. Vicor develops diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

The study, titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," was conducted under a collaborative agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. The goal of the study was to evaluate the ability of Vicor's PD2i nonlinear algorithm to predict cardiac events in the 537 chronic heart failure patients enrolled in the MUSIC Trial; MUSIC Trial participants were followed for an average period of 44 months. The conclusion of the University of Rochester researchers who conducted the study is that the PD2i nonlinear algorithm and software is predictive of total mortality, cardiac death, and heart failure death in patients with left ventricular ejection fraction of less than or equal to 35%. With a P value of 0.004 the study results are highly statistically significant.

Commenting on the study and its results, Wojciech Zareba, M.D. Ph.D. the Principal Investigator at the University of Rochester said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Currently, only about 30-40% of heart failure patients eligible for this therapy receive devices. Testing heart failure patients using the PD2i should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i test results."

"We're extremely pleased with the results achieved in this study. Researchers from the University of Rochester and Vicor scientists are studying these initial results to determine whether the resulting data will support a 510(k) submission to the Food and Drug Administration (FDA) for a marketing claim. What we have achieved may broaden the market for the PD2i Analyzer as a diagnostic that will significantly contribute to cardiologists in their assessment of treatment options for heart failure patients," stated Mr. Fater.


'/>"/>

Contact: Robin Schoen
schoenpr@comcast.net
215-504-2122
Vicor Technologies, Inc.
Source:Eurekalert

Related biology news :

1. NIH awards UC $9 million grant to improve patient point-of-care technologies
2. Patent Issued for e-Smart Technologies, Inc.s First Biometric Match-on-Card Technology
3. Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar
4. e-Smart Technologies Responds to Press Release Issued By IDsmart LLC
5. e-Smart Technologies, Inc. Responds to Information Subpoenas From Securities & Exchange Commission
6. e-Smart(R) Technologies, Inc., Announces Next Generation Superthin Polyimide Flexible Circuit Biometric Super Smart Card(TM) card, the i am(TM) Card.
7. Material Technologies Holds First Electrochemical Fatigue Sensor Training for Private Inspection Firms
8. e-Smart(R) Technologies Delivers Its New Super Smart Card(TM) in South Korea.
9. e-SMART Technologies Continues Delivery of Its New Super SMART Card in South Korea
10. Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs
11. Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... are characterized by a wide range of overlapping clinical features. The advancement of ... in the field of NDD research and testing. , However, designing a ...
(Date:7/16/2017)... ... 16, 2017 , ... OHAUS Corporation, a leading worldwide manufacturer ... new line of Rocking and Waving Shakers today. , Five New Models Available ... digital) for laboratory applications in a variety of environmental conditions. Rocking shakers provide ...
(Date:7/14/2017)... ... July 13, 2017 , ... Dr. Joshua Mondlick has introduced ... into his practice, Mondlick Perio, in the Phoenix area. Dr. Mondlick is ... and only FDA cleared laser treatment to re-grow bone and with significantly less pain ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... ... URAC accreditation in Specialty Pharmacy. URAC is the independent leader in promoting healthcare ... demonstrated a comprehensive commitment to quality care, improved processes and better patient outcomes. ...
Breaking Biology Technology: